Cookie Policy
We value the protection of our users' privacy and our cookie usage policy. Our website uses cookies and other similar technologies to distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and helps us to improve the quality of our service. For more information, please click and see our Cookie Policy.

Zybio at Medlab ME 2025: Together Towards Tomorrow

February 08, 2025 Zybio News

During February 3-6, 2025, Medlab Middle East 2025 witnessed thousands of visits to Zybio’s flagships in Core Lab Solution, Mass Spectrometry Family and Molecular Livestock Solution based on 8 product lines at booth Z4 B40. We are honored to have the appreciation and trust from our partners and healthcare professionals, which, in turn, motivate Zybio team to be further dedicated to facilitating laboratory diagnostics with constant innovation, upgrading and launching of new products. 

Core Lab Solutioin: Designed for Efficient, Streamlined, Flexible Testing

Zybio’s Core Lab Solution, designed to streamline laboratory testing from rapid screening to accurate measurement of biomarkers, is equipped with state-of-the-art instruments from Hematology, Urinalysis, Coagulation, Chemistry, CLIA to POCT. Each platform features several new products with better performance launched in recent years and witnesses continuous upgrading of reliability and function design. Based on flexibly integration of instruments of various throughput, the customizable Core Lab Solution can be an ideal fit for laboratories of various scales. 

Mass Spectrometry Family: Flagships Based on Recognized Technologies

With 32 patents for Zybio’s MALDI-TOF system and a database of over 4,000 local microbial species, Zybio’s MALDI-TOF analyzer EXS 2600 is well-received at home and abroad, such as in Turkey, the Czech Republic, Poland, Austria, Croatia, Serbia, Thailand, Indonesia, etc. Furthermore, Zybio is working on expanding the mass spectrometry family to include nucleic acid mass spectrometry for more precise detection of genetic markers, triple quadrupole system for applications like amino acids, newborn screening and drug development, and teaching mass spectrometry system for facilitating education and application in universities. 

Molecular Livestock Solution: Reliable Animal Health Defender

Zybio’s Molecular Livestock Solution covers sample collection, automatic nucleic acid extraction and real-time quantitative detection based on constantly upgrading and expanding devices and reagents. Based on Zybio’s Molecular Livestock Solution, different samples including swabs, body fluids, blood, carcass tissue, farm environment, etc. can be applied, and the extraction program will take only around 17 minutes to deliver reliable results of great performance. Furthermore, different testing items are provided by Zybio such as ASFV, AIV, WSSV and other commonly seen pathogens. With customized solutions available with rapid delivery, Zybio’s comprehensive offerings ensure precision, speed, and adaptability for all molecular diagnostic needs.

Together Towards Tomorrow: Zybio Middle East and Africa Distributors Conference

While Medlab Middle East 2025 unveils Zybio’s first expo in 2025, a distributor conference was held to address strategy of growth and success in better serving customers with continuous diagnostic innovations and integrated solutions. 

Zybio started international expansion in 2018 and subsidiaries in countries such as Indonesia, Thailand, Philippines, Brazil, Mexico, Pakistan, Russia and Netherlands have been set up to facilitate local operations. Currently, an integrated team of Sales, Application and Service of over 300 engineers worldwide are serving the local markets.

Zybo’s products, solutions and services have been widely applied in over 20,000 healthcare facilities in more than 100 countries and regions worldwide. 

Dedication to Accuracy, Zybio has been and will always be committed to improvement of total laboratory diagnostic solution and increasingly excellent products and services for partners. In this way, we aim to jointly facilitate the healthcare industry.